Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report

Rhea-AI Summary

Agenus (Nasdaq: AGEN) will release its fourth quarter and full year 2022 financial results on March 14, 2023, before the market opens. The company specializes in immuno-oncology, targeting cancer and infectious diseases. Following the results, Agenus executives will host a conference call and webcast at 8:30 a.m. ET to discuss the financial outcomes and provide a corporate update. Investors can access the call via dial-in numbers or through a live webcast available on the company’s official website. This event is pivotal for stakeholders, as it will outline key financial metrics and future strategies in the competitive biotechnology landscape.

Positive

• The upcoming financial results may highlight significant progress in Agenus' immunological pipeline.
• Agenus is equipped with advanced antibody discovery platforms and a GMP manufacturing facility.

Negative

• None.

Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced the Company will release its fourth quarter and full year 2022 financial results before the market opens on Tuesday, March 14, 2023. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Conference Call
Dial-in numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)
Conference ID: 2699739

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/p9dyor73.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact
Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

FAQ

What are Agenus' upcoming financial results release dates?

Agenus will release its fourth quarter and full year 2022 financial results on March 14, 2023.

When is the Agenus conference call scheduled?

The conference call is scheduled for March 14, 2023, at 8:30 a.m. ET.

How can investors participate in the Agenus financial conference call?

Investors can participate via dial-in numbers or by accessing the live webcast on Agenus' official website.

What is the focus of Agenus as a company?

Agenus is focused on the discovery and development of immuno-oncology therapies targeting cancer and infectious diseases.